and OxfordVR Combine and Raise Series B to Create Largest VR Delivery Platform for Evidence-Based Digital Therapeutics
Summary
For people with Serious Mental Illness (SMI), ordinary tasks such as using public transit, spending time with family or leaving home can be difficult. OxfordVR, whose gameChange product was recently granted FDA Breakthrough Device designation, will treat patients using automated cognitive-behavioral VR therapy. These therapies can be delivered by a wide range of clinical staff, peer group members and at home.The combined company will be led by BehaVR Founder and CEO Aaron Gani. Ganis leadership team will include psychiatrist, researcher and author Dr. Daniel Freeman, PhD.The demand for mental health services far outstrips available resources. BehaVR is the first immersive digital therapeutics company to deliver these treatments on an integrated platform that simplifies the patient experience, enables clinician oversight, and generates patient-specific care plans and measurable outcomes.